178 related articles for article (PubMed ID: 24997889)
21. Approaches to optimal dosing of vitamin K antagonists.
Witt DM
Semin Thromb Hemost; 2012 Oct; 38(7):667-72. PubMed ID: 22893509
[TBL] [Abstract][Full Text] [Related]
22. Oral anticoagulant treatment - evaluating the knowledge of patients admitted in physical medicine and rehabilitation units.
Janoly-Duménil A; Bourne C; Loiseau K; Luauté J; Sancho PO; Ciancia S; Caillet F; Boisson D; Rioufol C; Plauchu MM; Rode G; Jacquin-Courtois S
Ann Phys Rehabil Med; 2011 May; 54(3):172-80. PubMed ID: 21474406
[TBL] [Abstract][Full Text] [Related]
23. Optimizing quality care for the oral vitamin K antagonists (VKAs).
Pengo V; Denas G
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):332-338. PubMed ID: 30504329
[TBL] [Abstract][Full Text] [Related]
24. Knowledge and wishes of patients as regards vitamin K antagonists: a cross-sectional survey in Western Brittany, France.
Cornec B; Nabbe N; Oger E
Therapie; 2011; 66(4):363-8. PubMed ID: 21851801
[TBL] [Abstract][Full Text] [Related]
25. Decision making for oral anticoagulants in atrial fibrillation: the ATA-AF study.
Gussoni G; Di Pasquale G; Vescovo G; Gulizia M; Mathieu G; Scherillo M; Panuccio D; Lucci D; Nozzoli C; Fabbri G; Colombo F; Riva L; Baldo CI; Maggioni AP; Mazzone A;
Eur J Intern Med; 2013 Jun; 24(4):324-32. PubMed ID: 23684591
[TBL] [Abstract][Full Text] [Related]
26. [Frequency of use of oral vitamin K antagonists in patients with atrial fibrillation and cognitive function disturbances].
Gorzelak P; Zyzak S; Krewko Ł; Mozdzan M; Broncel M
Pol Merkur Lekarski; 2014 May; 36(215):302-6. PubMed ID: 24964505
[TBL] [Abstract][Full Text] [Related]
27. Risk factors of vitamin K antagonist overcoagulation. A case-control study in unselected patients referred to an emergency department.
Cadiou G; Varin R; Levesque H; Grassi V; Benichou J; Tiret I; Dieu B; Lecam-Duchez V; Borg JY; Muller JM; Benhamou Y; Marie I
Thromb Haemost; 2008 Oct; 100(4):685-92. PubMed ID: 18841293
[TBL] [Abstract][Full Text] [Related]
28. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
29. [Vitamin K antagonists: from discovery to pharmacogenetics].
Moreau C; Loriot MA; Siguret V
Ann Biol Clin (Paris); 2012 Oct; 70(5):539-51. PubMed ID: 23047901
[TBL] [Abstract][Full Text] [Related]
30. Decreased procoagulant phospholipids in patients treated by vitamin K antagonists.
Rousseau A; Woodhams B; Paunet-Bobo M; Van Dreden P; Bigot D; Leclerc S; Lenormand B; Vasse M
Thromb Res; 2012 Sep; 130(3):491-4. PubMed ID: 22551976
[TBL] [Abstract][Full Text] [Related]
31. [Outcomes after a 2-year pharmaceutical care program for patients taking vitamin K antagonist therapy? Community pharmacist's perception].
Mongaret C; Lepage C; Aubert L; Lestrille A; Slimano F
Ann Pharm Fr; 2018 Mar; 76(2):114-121. PubMed ID: 29395013
[TBL] [Abstract][Full Text] [Related]
32. Chronic vitamin K antagonist therapy and bleeding risk in ST elevation myocardial infarction patients.
Karrowni W; Wang TY; Chen AY; Thomas L; Saucedo JF; El Accaoui RN
Heart; 2015 Feb; 101(4):264-70. PubMed ID: 25336230
[TBL] [Abstract][Full Text] [Related]
33. [Anticoagulant clinics are they effective in France? Performance evaluation of six anticoagulant clinics concerning the management of vitamin K antagonists].
Cambus JP; Magnin D; Ambid-Lacombe C; Bura A; Desgrippes F; Schneller JM; Benhamou Y; Flaujac C; Horellou MH; De Raucourt E; Kaczan D; Astoul JM; Siguret V
Rev Med Interne; 2013 Sep; 34(9):515-21. PubMed ID: 23523077
[TBL] [Abstract][Full Text] [Related]
34. [Management of oral anticoagulants by elderly patients at home].
Pautas E; Naline C; Golmard JL; Montni A
Soins Gerontol; 2013; (104):11-5. PubMed ID: 24437006
[TBL] [Abstract][Full Text] [Related]
35. Vitamin K antagonists predispose to calciphylaxis in patients with end-stage renal disease.
Galloway PA; El-Damanawi R; Bardsley V; Pritchard NR; Fry AC; Ojha SK; Hiemstra TF
Nephron; 2015; 129(3):197-201. PubMed ID: 25720849
[TBL] [Abstract][Full Text] [Related]
36. Interaction of vitamin K antagonists and trimethoprim-sulfamethoxazole: ignore at your patient's risk.
Hale SF; Lesar TS
Drug Metabol Drug Interact; 2014; 29(1):53-60. PubMed ID: 24231121
[TBL] [Abstract][Full Text] [Related]
37. [Heterogeneity in the handling of vitamin-K-antagonists and of INR: the example of Quercy-Rouergue].
Watine J; Mokaddem W; Carriere P; Couaillac JP; Kristoffersen AH; Thue G; Sandberg S
Ann Biol Clin (Paris); 2013; 71(6):707-16. PubMed ID: 24342793
[TBL] [Abstract][Full Text] [Related]
38. Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate.
Majeed A; Meijer K; Larrazabal R; Arnberg F; Luijckx GJ; Roberts RS; Schulman S
Thromb Haemost; 2014 Feb; 111(2):233-9. PubMed ID: 24154891
[TBL] [Abstract][Full Text] [Related]
39. Modelling of vitamin K half-life in patients treated with vitamin K antagonists before hip fracture surgery.
Combettes E; Mazoit JX; Benhamou D; Beloeil H
Anaesth Crit Care Pain Med; 2015 Oct; 34(5):295-9. PubMed ID: 26638965
[TBL] [Abstract][Full Text] [Related]
40. Fever as a risk factor for increased response to vitamin K antagonists: a review of the evidence and potential mechanisms.
Self TH; Oliphant CS; Reaves AB; Richardson AM; Sands CW
Thromb Res; 2015 Jan; 135(1):5-8. PubMed ID: 25456000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
